Keywords: GlaxoSmithKline, Human Genome Sciences, Poison pill, Antibit=otic researchm Regorafenib, EU and USA filing, Colorectal cancer

News briefs: GlaxoSmithKline and Bayer

Article | 24 May 2012

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile takeover offer for Human ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in